Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- Trading 34% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 7.5% — below-average profitability
- Revenue growing at 12% annually
Kamada Ltd. - Ordinary Shares (KMDA) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $470 million . Key value metrics: P/E ratio 23.3, P/B ratio 1.75, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Kamada Ltd. - Ordinary Shares — Fundamental Analysis Summary
Kamada Ltd. - Ordinary Shares (KMDA) is currently trading 34% above its Graham Number of $6.06, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 23.3x.
On financial health, KMDA shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 7.5% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for KMDA is 76/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KMDA reports a solid gross margin of 42.3% (sector average: 33.5%) and a solid operating margin of 14.5%.
KMDA shows revenue growing at 12% year-over-year, with earnings growing at 40%.